The Pediatric Clinical Trials program would encompass any interventional trials in children with acute or chronic renal disease. Specific areas to be included:
Congenital and hereditary disorders in children – renal dysplasia, cystic kidney diseases (not polycystic kidney disease, which is covered under Dr. Meyers’ program); congenital nephrotic syndrome, hereditary glomerulopathy, Alport syndrome; metabolic disorders such as cystinosis. Cystinuria, hyperoxaluria, Fanconi syndrome; primary and secondary kidney involvement in disorders of phosphorus, calcium and vitamin D; tubular disorders of electrolyte transport and regulation such as Bartter’s syndrome, Liddle’s syndrome, renal tubular acidosis.
Renal Disease progression in children – treatment interventions in the pathogenesis and pathophysiology of renal injury, disease progression and complications.
Glomerulonephritides in children – minimal change nephrotic syndrome, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, IgA nephropathy, and hemolytic uremic syndrome. (Lupus nephritis would be covered under Dr. Meyers’ program).
Acute renal failure in children – treatment interventions.
Pediatric chronic renal insufficiency and End Stage Renal Disease (ESRD) – treatment interventions for slowing disease progression and for the complications of chronic renal failure, including dialysis and transplantation. Areas of interest would include nutritional management, growth and growth failure, cardiovascular complications, neurocognitive complications, disease recurrence post-transplant, and complications post-transplantation.
Renal Function Assessment in Children – studies of methods to measure glomerular filtration rate (invasive or surrogate, noninvasive methods), urinary protein excretion; renal biopsy techniques and tissue assessment; renal imaging.
For more information, contact Dr. Marva Moxey-Mims, Pediatric Nephrology Program Director.
